0000000000704441

AUTHOR

M. Benavides

showing 1 related works from this author

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

2008

Abstract Purpose: To determine the recommended dose, cardiac safety, and antitumor activity of nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and the anti-HER-2 monoclonal antibody trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) and metastatic breast cancer (MBC). Experimental Design: Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC with a baseline left ventricular ejection fraction (LVEF) >50% received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and TLC-D99 every 3 weeks for 6 cycles. LVEF monitoring was done every 3 weeks for the first 18 weeks and every 8 w…

AdultCancer Researchmedicine.medical_specialtyHeart DiseasesPaclitaxelUrologyBreast NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticDisease-Free Survivalchemistry.chemical_compoundBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinNeoplasm Metastasisskin and connective tissue diseasesAgedEjection fractionbusiness.industryAntibodies MonoclonalGenes erbB-2Middle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerUp-RegulationSurgeryOncologyPaclitaxelchemistryDoxorubicinHeart failureFemalemedicine.symptombusinessmedicine.drug
researchProduct